Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Roadmap to Integrate Diversity, Equity, and Inclusion in Hematology Clinical Trials: An ASH Initiative Submitted on Behalf of the Entire Roadmap to Improve DEI in Clinical Trials Working Group

Alice Kuaban, Alysha Croker, Jeffrey Keefer, Leonard A. Valentino, Alan E. Mast, Stephanie Valer Seremetis

Blood (2024) 144 (Supplement 1): 5013.

https://doi.org/10.1182/blood-2024-201731

Published: 2024

Journal Articles

Use of Data Enhancement for Emerging Study Methodologies That Compare Clinical Trial and Real-World Data

Domitilla Masi, Nikita Jeswani, Catherine Hogg, Kirill Dushkin, Jeffrey Keefer

Blood (2022) 140 (Supplement 1): 13023–13024.

https://doi.org/10.1182/blood-2022-163288

Published: 2022

Journal Articles

Clinical Evaluation of Combined Epigenetic Therapies on the Induction of Fetal Hemoglobin in Patients with Hematologic Malignancies

Katharine Rose Press, BA, Jeffrey Keefer, MD PhD, Steven D. Gore, MD, Hetty E. Carraway, MD MBA, Sarah Sakoian, Thomas Prebet, MD

Blood (2015) 126 (23): 960.

https://doi.org/10.1182/blood.V126.23.960.960

Published: 2015

Journal Articles

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson

Joshua J. Field, Gene Lin, Maureen M. Okam, Elaine Majerus, Jeffrey Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, David G. Nathan

Blood (2013) 121 (17): 3329–3334.

https://doi.org/10.1182/blood-2012-11-465963

Published: 2013

Includes: Supplemental data

Journal Articles

Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia

Abdullah Kutlar, MD, Kenneth I. Ataga, MD, Marvin Reid, PhD, Loray A Blair-Britt, MD, Elliott Vichinsky, MD, Lynne Neumayr, MD, Richard J. Labotka, MD, MS, Jonathan Glass, MD, FACP, Andrea Small-WIlliams, MBBS, DM(HAEM), Jeffrey Keefer, MD, PhD, Ling Shen, MD, Michael S Boosalis, PhD, Audrey Thomson, BSc, Patrick Bobbitt, BS, Wayne Wallis, MD, Elsa Johnson, MBA, Ronald J Berenson, MD, Susan P Perrine, MD

Blood (2010) 116 (21): 943.

https://doi.org/10.1182/blood.V116.21.943.943

Published: 2010

Journal Articles

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

Susan Perrine, MD, William C Welch, PhD, Jeffrey Keefer, MD, PhD, Robin L Downey, MD, Michael S Boosalis, PhD, Sally Case, RN, Douglas V Faller, MD, PhD, Ronald Berenson, MD

Blood (2008) 112 (11): 130.

https://doi.org/10.1182/blood.V112.11.130.130

Published: 2008

Journal Articles

C/EBPα:AP-1 Leucine Zipper Heterodimers Bind Novel DNA Elements, Activate the PU.1 Promoter, and Direct Monocyte Lineage Commitment More Potently Than C/EBPα Homodimers or AP-1.

Alan D. Friedman, MD, Dong Hong Cai, M.D., Ph.D., Dehua Wang, M.D., M.Sc., Jeffrey Keefer, M.D., Ph.D., Christine Yeamans, M.D., Kortney Hensley

Blood (2007) 110 (11): 1232.

https://doi.org/10.1182/blood.V110.11.1232.1232

Published: 2007

NARROW

The Roadmap to Integrate Diversity, Equity, and Inclusion in Hematology Clinical Trials: An ASH Initiative Submitted on Behalf of the Entire Roadmap to Improve DEI in Clinical Trials Working Group

Use of Data Enhancement for Emerging Study Methodologies That Compare Clinical Trial and Real-World Data

Clinical Evaluation of Combined Epigenetic Therapies on the Induction of Fetal Hemoglobin in Patients with Hematologic Malignancies

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson

Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

C/EBPα:AP-1 Leucine Zipper Heterodimers Bind Novel DNA Elements, Activate the PU.1 Promoter, and Direct Monocyte Lineage Commitment More Potently Than C/EBPα Homodimers or AP-1.

Email alerts

ASH Publications

American Society of Hematology

The Roadmap to Integrate Diversity, Equity, and Inclusion in Hematology Clinical Trials: An ASH Initiative Submitted on Behalf of the Entire Roadmap to Improve DEI in Clinical Trials Working Group

Use of Data Enhancement for Emerging Study Methodologies That Compare Clinical Trial and Real-World Data

Clinical Evaluation of Combined Epigenetic Therapies on the Induction of Fetal Hemoglobin in Patients with Hematologic Malignancies

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson

Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

C/EBPα:AP-1 Leucine Zipper Heterodimers Bind Novel DNA Elements, Activate the PU.1 Promoter, and Direct Monocyte Lineage Commitment More Potently Than C/EBPα Homodimers or AP-1.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only